MALARIA ERADICATION
THROUGH VACCINATION
Sanaria's vaccines are intended to be used to prevent malaria in individuals and, in combination with other malaria control measures, to halt transmission of and eliminate malaria from communities.
3-Dose Malaria Vaccine Demonstrates Safety, Efficacy in West Africa
“Our study shows that the vaccine can be given to malaria-experienced adults in a highly endemic area and still provide protection, which is difficult and complicated as these individuals already have significant immune responses to malaria parasites that must be overcome by a vaccine for it to be successful,” said Dr. Laurens.
Trends in Parasitology Spotlights Sanaria’s In Vitro Paper Published in Nature
"The whole-sporozoite-based vaccine approach has been limited by the difficulty of mass production of infectious sporozoites from infected mosquitoes. Eappen et al. describe a method for producing a large quantity of sporozoites in vitro, which opens new areas of investigations in sporozoite biology and large-scale sporozoite production for vaccine development."
A randomized controlled trial showing safety and efficacy of a whole sporozoite vaccine against endemic malaria
Published in Science Translational Medicine - A highly effective malaria vaccine remains elusive despite decades of research. Plasmodium falciparum sporozoite vaccine (PfSPZ Vaccine), a metabolically active, nonreplicating, whole parasite vaccine demonstrated safety and vaccine efficacy (VE) against endemic P. falciparum for 6 months in Malian adults receiving a five-dose regimen.
INFECTIOUS MALARIA SPOROZOITES PRODUCED WITHOUT MOSQUITOES PROVIDE GROUND-BREAKING PROGRESS FOR MALARIA VACCINES AND BIOLOGY RESEARCH
Scientists from Sanaria Inc., and collaborators at multiple institutions publish results in Nature reporting “In vitro production of infectious Plasmodium falciparum sporozoites.”
Employees of the Month: Mei-Chun Chen and Ramon Dizon Jr.
The Sanaria employees of the month for October 2023 are Mei-Chun Chen and Ramon Dizon Jr.. Mei is a member of the clinical team at Sanaria and was nominated for employee of the month for her immeasurable contributions to the success of Sanaria. Ramon is a member of the Materials Management team and was nominated for employee of the month for performing his duties competently, expeditiously and with a smile, always pleasant, always willing to help and always joy to work with.
Sanaria and Seattle Children’s Research Institute host the first live i-PfSPZ-C meeting since 2019 in Seattle, WA, USA
From November 3rd-4th, 2022, Sanaria and Seattle Children's Research Institute hosted 289 researchers from 86 institutions from 28 countries in person and virtually at the International (i) - Plasmodium falciparum (PfSPZ) - Consortium (C) meeting to further a collaborative approach for presentation of data and setting research and clinical development strategies for PfSPZ based vaccines and products.
An Urgent Need for Malaria Vaccines
Sanaria has an innovative approach to malaria vaccines using Plasmodium falciparum (Pf) sporozoites (SPZ) as the platform technology for immunizing people against malaria infection. The proven effective results of this approach are documented in Sanaria’s publications.
Global Collaboration: The I-PfSPZ Consortium
Semi-annually, Sanaria organizes the international PfSPZ Consortium (i-PfSPZ-C) meeting for our partners, collaborators and funders where we analyze, present and discuss our findings prior to publication. The i-PfSPZ-C allows our collaborators and partners to share their work, modify research and clinical plans based on the consortium efforts and map out future funding needs.
Subscribe
Our Malaria Vaccine Pipeline
Innovative routes to success. A major impact in global health.